Immune Design Corp. (NASDAQ:IMDZ) shares shot up 3.7% during trading on Thursday . The stock traded as high as $7.95 and last traded at $7.90, with a volume of 97,419 shares traded. The stock had previously closed at $7.62.

Several research firms have recently commented on IMDZ. Jefferies Group restated a “buy” rating and set a $20.00 price target on shares of Immune Design Corp. in a research report on Sunday, May 29th. Cowen and Company reiterated an “outperform” rating on shares of Immune Design Corp. in a research note on Wednesday, April 27th. Leerink Swann reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Thursday, May 12th. Zacks Investment Research cut Immune Design Corp. from a “hold” rating to a “sell” rating in a research note on Tuesday, July 12th. Finally, Wells Fargo & Co. reiterated a “buy” rating on shares of Immune Design Corp. in a research note on Wednesday, May 11th. One analyst has rated the stock with a sell rating and four have issued a buy rating to the company’s stock. Immune Design Corp. currently has a consensus rating of “Buy” and an average target price of $24.00.

The firm’s market cap is $159.21 million. The firm’s 50 day moving average price is $8.31 and its 200-day moving average price is $11.23.

Immune Design Corp. (NASDAQ:IMDZ) last issued its quarterly earnings results on Tuesday, May 10th. The company reported ($0.61) earnings per share for the quarter, beating the Thomson Reuters’ consensus estimate of ($0.62) by $0.01. On average, equities analysts predict that Immune Design Corp. will post ($2.70) EPS for the current year.

A hedge fund recently raised its stake in Immune Design Corp. stock. Jennison Associates raised its stake in shares of Immune Design Corp. (NASDAQ:IMDZ) by 0.6% during the third quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission. The fund owned 202,683 shares of the company’s stock after buying an additional 1,224 shares during the period. Jennison Associates owned about 1.01% of Immune Design Corp. worth $2,473,000 as of its most recent filing with the SEC.

Immune Design Corp. is a clinical stage immunotherapy company with next-generation in vivo approaches designed to enable the body’s immune system to fight disease. The Company is developing multiple product candidates from its two discovery platforms, ZVex and GLAAS, which it believes have the potential to treat a broad patient population either as individual therapies or in combination with other immuno-oncology mechanisms of action.

Get Analysts' Upgrades and Downgrades Daily - Enter your email address below to receive a concise daily summary of analysts' upgrades, downgrades and new coverage with's FREE daily email newsletter.